drugset / Trial / NCT00031889

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

NCT00031889

Phase 2 Completed 5 enrolled Swiss Cancer Institute
RandomizedFactorialOpen-labelTreatment

Summary

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using exemestane plus bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if exemestane is more effective with or without bicalutamide in treating prostate cancer. PURPOSE: Randomized phase II trial to study the effectiveness of exemestane with or without bicalutamide in treating patients who have stage IV prostate cancer that has been previously treated with hormone therapy or surgery.

Timeline

Start
2001-08
Primary completion
2002-06
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bicalutamide Other / unclassified Oral
Comparator Exemestane Small molecule Oral

Indications